AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02664935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib
Description: ALK/MET/ROS1 Inhibitor
Study NCT02664935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib
Description: MEK Inhibitor
Study NCT02664935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Taxane, anti-mitotic cytotoxic chemotherapy
Study NCT02664935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5363
Description: AKT Inhibitor
Study NCT02664935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: EGFRm+ T790M+ Inhibitor
Study NCT02664935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Anti-PDL1
Study NCT02664935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitravatinib
Description: VEGFR Inhibitor
Study NCT02664935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6738
Description: ATR inhibitor
Study NCT00852449 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: restrictive and liberal fluid therapy
Description: In both group, when hypovolemia is suspected (peak aortic velocity variation > 13%): fluid bolus (hydroxyethyl starch 130/0.4/6%) according to a predefined algorithm designed to maintain peak aortic velocity \< 13% and no further increases in SV
Study NCT05173558 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Uninterrupted motionless standing
Description: Participants remained 20 minutes of uninterrupted motionless standing
Study NCT05173558 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Uninterrupted motionless sitting
Description: Participants remained 20 minutes of uninterrupted motionless sitting
Study NCT05173558 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sit-to-stand transitions
Description: 20 minutes of sit-to-stand transitions (1 minute sitting with 1 minute standing)
Study NCT00684021 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Adult stem cells
Description: One time infusion of approximately 150 million total nucleated cells (TNC) in 30 ml of 5% HSA/saline solution
Study NCT00684021 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One time infusion of 30 ml of HSA (5%)
Study NCT00891904 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: Given IV
Study NCT00891904 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic body radiation therapy
Description: Undergoing Radiotherapy
Study NCT04123392 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Decitabine was administered at 20mg/m2/day on days -14 and -10.
Study NCT04123392 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Busulfan (BU)
Description: Busulfan was administered at 3.2 mg/kg/day on days -7 to -4.
Study NCT04123392 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan (BU)
Description: Busulfan was administered at 3.2 mg/kg/day on days -7 to -4.
Study NCT04123392 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide (CY)
Description: Cyclophosphamide was administered at 60 mg/kg/day on days -3 to -2.
Study NCT04123392 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CY)
Description: Cyclophosphamide was administered at 60 mg/kg/day on days -3 to -2.
Study NCT03965611 — intervention group
Intervention type: PROCEDURE
Intervention: Oropharyngeal swab
Description: Will be performed by trained paramedical staff using sterile swabs with transport medium ESwab® (Becton, Dickinson and Company, New Jersey, USA). Swabs will be stored at -80°C until DNA extraction.
Study NCT03965611 — intervention group
Intervention type: PROCEDURE
Intervention: Rectal swab
Description: Will be performed by trained paramedical staff using sterile swabs with transport medium ESwab® (Becton, Dickinson and Company, New Jersey, USA). Swabs will be stored at -80°C until DNA extraction.
Study NCT03965611 — intervention group
Intervention type: PROCEDURE
Intervention: Disability rating scale (DRS-F)
Description: Will be assessed at day 90 +/- 7 days.
Study NCT04292678 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Progressive muscle relaxation
Description: The progressive muscle relaxation intervention will last for 20 minutes and comprise sessions involving tensing and relaxing the body with deep breathing. The participants will perform progressive muscle relaxation for each body part in order, starting with the facial muscles and head, followed by neck, shoulders, chest, abdomen, legs, and feet; all muscle tension and relaxation procedures were performed accompanied with deep breathing. The participants will be instructed to tense a specified group of muscles for 5 s and relax it for 10 s while breathing out. Throughout this exercise, the participants will visualize a wave of relaxation flowing over their body using the deep-breathing technique.
Study NCT04292678 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Attention matched control
Description: Caregivers of patients with advanced cancer will receive only a training group session about general cancer information such as risk factors, treatment methods, and treatment-related side effects, lasting 20 minutes first week of the study.
Study NCT03141008 — intervention group
Intervention type: OTHER
Intervention: Fibroscan changes with different diets
Description: Observational study of liver fat and stiffness and cardiometabolic parameters comparing two different standard of care dietary regimens
Study NCT00718354 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Description: Once daily dose of 1mg/Kg of body weight for 6 months
Study NCT00718354 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Chemotherapy
Description: Investigator's discretion
Study NCT03339128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eluxadoline
Description: Oral tablets
Study NCT03339128 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral tablets
Study NCT02795429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spartalizumab
Description: Spartalizumab administered via intravenous (i.v.) infusion once every 3 weeks (Q3W)
Study NCT02795429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capmatinib
Description: Capmatinib administered orally as a tablet on a continuous twice daily (BID) dosing schedule
Study NCT03167931 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI + transcranial Magnetic Stimulation
Description: Healthy subjects undergo 2 sessions of MRI + transcranial Magnetic Stimulation + transcranial electric stimulation + electroencephalogram. The 2 sessions are performed with an interval of 3 to 7 days.
Study NCT03167931 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: transcranial electric stimulation + electroencephalogram
Description: Healthy subjects undergo 2 sessions of MRI + transcranial Magnetic Stimulation + transcranial electric stimulation + electroencephalogram. The 2 sessions are performed with an interval of 3 to 7 days.
Study NCT00793000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04287881
Description: 75 mg oral dose (prepared solution) given once
Study NCT00793000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo to match 75 mg oral dose (prepared solution), given once
Study NCT00793000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04287881
Description: 150 mg oral dose (prepared solution) given once
Study NCT00793000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo to match 150 mg oral dose (prepared solution), given once
Study NCT00793000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04287881
Description: 300 mg oral dose (prepared solution) given once
Study NCT00793000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo to match 300 mg oral dose (prepared solution), given once
Study NCT00793000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04287881
Description: 750 mg oral dose (prepared solution) given once
Study NCT00793000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo to match 750 mg oral dose (prepared solution), given once
Study NCT00793000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04287881
Description: 1000 mg oral dose (prepared solution) given once
Study NCT00793000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo to match 1000 mg oral dose (prepared solution), given once
Study NCT00793000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04287881
Description: 1250 mg oral dose (prepared solution) given once
Study NCT00793000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo to match 1250 mg oral dose (prepared solution), given once
Study NCT00793000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04287881
Description: 1500 mg oral dose (prepared solution) given once
Study NCT00793000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo to match 1500 mg oral dose (prepared solution), given once
Study NCT00793000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04287881
Description: 1000 mg based on safety and PK from previous cohorts; oral dose (prepared solution) given once
Study NCT03200600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 10 mg is administered before anesthesia induction.
Study NCT03200600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal saline
Description: Normal saline 2 ml is administered before anesthesia induction.
Study NCT03200600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flurbiprofen axetil
Description: Flurbiprofen axetil 50 mg is administered before the start of surgery. Postoperative analgesia is provided with a patient-controlled analgesia pump, which is established with 100 ml of 1.25 μg/ml sufentanil and 2 mg/ml flurbiprofen axetil, programmed to deliver a 2 ml bolus with a lockout interval of 6-8 min and a background infusion of 1 ml/h.
Study NCT03200600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lipid microsphere
Description: Lipid microsphere 5 ml is administered before the start of surgery. Postoperative analgesia is provided with a patient-controlled analgesia pump, which is established with 100 ml of 1.25 μg/ml sufentanil and 20 ml lipid microsphere, programmed to deliver a 2 ml bolus with a lockout interval of 6-8 min and a background infusion of 1 ml/h.
Study NCT00988520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium bromide
Description: Continuous intravenous infusion initiated at 7 μg/kg/min and adjusted to maintain muscle relaxation
Study NCT00988520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium bromide
Description: Intubation dose of 0.6 mg/kg injection
Study NCT00988520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium bromide
Description: Intubation dose of 0.9 mg/kg injection
Study NCT00988520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: 0.5-2.0% intravenous maintenance anesthesia
Study NCT00988520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: 4010 mg/kg/hr intravenous maintenance anesthesia
Study NCT02234245 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Telemedicine System
Description: Telemedicine System is used in remote monitoring group
Study NCT01435382 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-04950615 (RN316)
Description: Dose A - single-dose intravenous infusion
Study NCT01435382 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-04950615 (RN316)
Description: Dose B - single-dose subcutaneous injection
Study NCT01435382 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-04950615 (RN316)
Description: Dose C - single-dose subcutaneous injection
Study NCT01435382 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-04950615 (RN316)
Description: Dose D - single-dose subcutaneous injection
Study NCT00780312 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physiotherapy
Description: 50 patients in this group get the existing hospital treatment: A 10 minute instruction in mouth opening exercises by a nurse. Furthermore they receive in all 6-7 sessions of physiotherapy treatment for a 5-6 weeks period with sessions of approximately 45 minutes. 2 months after having completed radiotherapy treatment they receive a final physiotherapy treatment. The treatment consists of instruction in active and passive exercises for mouth opening, stretching exercises for the neck and shoulder region, tongue exercises, mimic exercises, self administered lymph drainage and softening of fibrotic tissue.
Study NCT00416910 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Filgrastim
Study NCT00416910 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fludarabine
Study NCT00416910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Study NCT00416910 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Study NCT00416910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Study NCT00416910 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mitoxantrone
Study NCT00416910 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Study NCT02976038 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: elamipretide
Description: 40 mg, subcutaneous injections (in the abdomen) daily for the shortest of the following: 260 weeks; regulatory approval and commercial availability of elamipretide in the subject's respective country; or termination of the clinical development for elamipretide in subjects with PMD.
Study NCT03632889 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: GoToSleep Program
Description: For the control group only the sleep hygiene handout will be given in this arm. For the computerized group a sleep hygiene handout along with assess to the GoToSleep online program.
Study NCT03473054 — intervention group
Intervention type: OTHER
Intervention: Web-based Mindfulness Course
Description: The intervention is a therapist led, web-based MBI course, delivered asynchronously via a series of online videos. The Be Mindful course is a four-week mindfulness course based on the Mindfulness-Based Stress Reduction and Mindfulness-Based Cognitive Therapy courses. The course has been positively evaluated and shown to reduce stress, anxiety, and depression for participants.~Participants complete ten online interactive videos (30 minutes each), twelve daily practice assignments (with supportive emails), five audio downloads, and online tools for reviewing progress. The minimum time to complete the course is four weeks, but people can take longer if they wish and will still have access to the resources.
Study NCT00566319 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PREPARE with pedometer
Description: Structured educational programme with pedometer use
Study NCT00566319 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PREPARE
Description: Structured educational programme
Study NCT03086811 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mother Infant Feeding Interaction very early training
Description: weekly training meetings on 4 topics:~1. What - proper nutrition and supplements for solid feeding phase (dietitian); What - the meaning of feeding to mother and infant (social worker).~2. Who - feeding skills - knowledge and actual practices~3. From anxiety to serenity - knowledge concerning growth patterns and common physical and emotional issues troubling parents of infants 4-12 months old.~4. Prevention of obesity and emotional eating - practical advise and tips.
Study NCT02826330 — intervention group
Intervention type: OTHER
Intervention: biomarkers
Description: fecal microbiota analysis antibodies in serum and saliva DNA polymorphisms
Study NCT03957928 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low fat cookie
Description: to determine the effects of low fat cookie consumption on satiety and metabolic parameters in overweight/obese adults
Study NCT03957928 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mango fruit
Description: to determine the effects of fresh mango pulp consumption on satiety and metabolic parameters in overweight/obese adults
Study NCT01322620 — intervention group
Intervention type: OTHER
Intervention: No treatment given
Description: No treatment given. Participants are to complete a questionnarie in the study.
Study NCT02177032 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rabies vaccine
Description: 12 doses of the PCEC rabies vaccine, administered ID (0.1mL for each injection) according to the 4-sites, 1-week regimen (i.e. 4 doses of vaccine; in both deltoids and anterolateral thigh areas, administered on days 1, 4, and 8).
Study NCT02177032 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rabies vaccines + Rabies immunoglobulins
Description: 12 doses of the PCEC rabies vaccine, administered ID (0.1mL for each injection) to adults only, according to the 4-sites, 1-week regimen (i.e. 4 doses of vaccine; in both deltoids and anterolateral thigh areas, administered on days 1, 4, and 8). HRIG will be administered on day 1 (before the first dose of the vaccine) in a dose of 20 IU/kg body weight intramuscularly into the gluteal muscle.
Study NCT02177032 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rabies vaccine
Description: 8 doses of the PCEC rabies vaccine, administered ID (0.1ml for each injection) according to the 2-sites, TRC, updated Thai Red Cross regimen (i.e. 2 doses of vaccine; in both deltoids, administered on days 1, 4, 8, and 29).
Study NCT02177032 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rabies vaccines + Rabies immunoglobulins
Description: 8 doses of the PCEC rabies vaccine, administered ID (0.1ml for each injection) to adults only, according to the 2-sites, TRC, updated Thai Red Cross regimen (i.e. 2 doses of vaccine; in both deltoids, administered on days 1, 4, 8, and 29). HRIG will be administered on day 1 (before the first dose of the vaccine) in a dose of 20 IU/kg body weight intramuscularly into the gluteal muscle.
Study NCT01054989 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fat/Inflammation effects
Description: Fat infusion (Intralipid) over 6 hours Fat orally (Soy bean oil) single dose LPS infusion for 10 minutes Glycerol infusion over 6 hours
Study NCT01054989 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Fat/Inflammation effects
Description: Fat infusion (Intralipid) over 6 hours Fat orally (Soy bean oil) single dose LPS infusion for 10 minutes Glycerol infusion over 6 hours
Study NCT01770418 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation with Concurrent Chemotherapy
Description: RADIATION: Proton Radiotherapy~Dose Level 1: 60 Gy (RBE) at 2.5 Gy(RBE) per fraction x 24 fractions~Dose Level 2: 60 Gy (RBE) at 3 Gy (RBE) per fraction x 20 fractions~Dose Level 3: 60.01 Gy (RBE) at 3.53 Gy (RBE) per fraction x 17 fractions~Dose Level 4: 60 Gy (RBE) at 4 Gy (RBE) per fraction x 15 fractions~CONCURRENT CHEMOTHERAPY:~Paclitaxel at a dose of 45 mg/m2 and Carboplatin at a dose of AUC 2 mg/min/ml (a total of 3-5 weekly doses) OR Cisplatin 50mg/m2 days 1, 8, 29, and 36 and Etoposide 50mg/m2 days 1-5, 29-33. For non squamous histology, Carboplatin AUC 5 on day 1 and Pemetrexed 500 mg/m2 on day 1 every 21 days OR Cisplatin 75 mg/m2 on day 1 and Pemetrexed 500 mg/m2 on day 1 every 21 days.~Adjuvant chemotherapy is optional.
Study NCT02835248 — intervention group
Intervention type: OTHER
Intervention: Fall Detection
Description: All participants will wear a device configured to detect falls.
Study NCT01109472 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: patient magazine
Description: patient magazine individually tailored to patient's prior feedback
Study NCT04592887 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: FLASH Radiotherapy
Description: FLASH radiotherapy is radiation treatment delivered at ultra-high dose rates compared to conventional radiation treatment.
Study NCT00494793 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: VAWC and mesh mediated fascial traction
Description: The first period of 2-5 days only the abdominal VAWC dressing is applied. On day 3-10 a polypropylene mesh is sutured to the fascial edges, between the two layers of the VAWC system, and tightened.~The VAWC dressing is changed and the mesh tightened every 2-3 days, resulting in gradual approximation of the fascial edges.~Finally the mesh is removed and the fascia is closed
Study NCT00897234 — intervention group
Intervention type: OTHER
Intervention: Mass Spectrometry
Description: Levels of Cathepsin D (CD) and fatty acid synthase (FAS) will be measured using isobaric tag labeling coupled with mass spectrometry. RNA concentration will be measured using spectrophometer and purity will be analyzed.
Study NCT03345134 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3475 and BCG
Description: combination treatment with MK-3475 and BCG after endoscopic ablation
Study NCT04950088 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hand-held video game device
Study NCT02204176 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise info
Description: Discussion:~* benefits of exercise~* types of exercise~* exercise guidelines~* components of an exercise session~* how to reduce risk of injuries